BR112019010830A2 - vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas - Google Patents

vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas

Info

Publication number
BR112019010830A2
BR112019010830A2 BR112019010830A BR112019010830A BR112019010830A2 BR 112019010830 A2 BR112019010830 A2 BR 112019010830A2 BR 112019010830 A BR112019010830 A BR 112019010830A BR 112019010830 A BR112019010830 A BR 112019010830A BR 112019010830 A2 BR112019010830 A2 BR 112019010830A2
Authority
BR
Brazil
Prior art keywords
production
swine influenza
methods
attenuated swine
influenza vaccines
Prior art date
Application number
BR112019010830A
Other languages
English (en)
Inventor
Timothy Leard Alton
Leonardo Liebstein-Bellia Martin
Michael Dorr Paul
Kim Taejoong
Mebatsion Teshome
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of BR112019010830A2 publication Critical patent/BR112019010830A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Abstract

esta divulgação fornece cepas de influenza suíno atenuado, particularmente, aquelas produzidas através de uma abordagem de genética reversa, composições compreendendo as mesmas e processos de produção e utilização das mesmas.
BR112019010830A 2016-11-30 2017-11-30 vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas BR112019010830A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428062P 2016-11-30 2016-11-30
PCT/US2017/064017 WO2018102586A1 (en) 2016-11-30 2017-11-30 Attenuated swine influenza vaccines and methods of making and use thereof

Publications (1)

Publication Number Publication Date
BR112019010830A2 true BR112019010830A2 (pt) 2019-10-01

Family

ID=61054473

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010830A BR112019010830A2 (pt) 2016-11-30 2017-11-30 vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas

Country Status (11)

Country Link
US (1) US10548967B2 (pt)
EP (1) EP3548078A1 (pt)
JP (1) JP2020502080A (pt)
KR (1) KR20190099218A (pt)
CN (1) CN110225765B (pt)
AU (1) AU2017367644A1 (pt)
BR (1) BR112019010830A2 (pt)
CA (1) CA3045315A1 (pt)
EA (1) EA201991319A1 (pt)
PH (1) PH12019501173A1 (pt)
WO (1) WO2018102586A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111321125B (zh) * 2020-02-03 2022-07-19 广州医科大学 重组流感病毒及其在疫苗中的应用
CN111269895B (zh) * 2020-02-03 2022-09-27 广州医科大学 甲型流感病毒减毒株及其作为骨架病毒和疫苗的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1144239A (en) * 1915-02-23 1915-06-22 Reinforced Inner Tube Company Inner tube for pneumatic tires.
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
PL205955B1 (pl) 2000-04-28 2010-06-30 St Jude Childrens Res Hospital Układ oparty na minimalnej liczbie plazmidów do wytwarzania infekcyjnych wirusów RNA o ujemnej nici, komórka gospodarza zawierająca taki układ, sposób wytwarzania wiriona wirusa RNA o ujemnej nici, sposób wytwarzania atenuowanego wirusa RNA o ujemnej nici, sposób wytwarzania zakaźnego wirusa o ujemnej nici do stosowania w szczepionkach i zastosowanie układu opartego na minimalnej liczbie plazmidów
DK3312272T3 (da) 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
MX349825B (es) * 2007-03-30 2017-08-15 Univ New York State Res Found Virus atenuados utiles para vacunas.
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2011044561A1 (en) * 2009-10-09 2011-04-14 The Research Foundation Of State University Of New York Attenuated influenza viruses and vaccines
EP2545176B1 (en) * 2010-03-08 2016-05-11 Yeda Research and Development Co. Ltd. Recombinant protein production in heterologous systems
WO2012145509A2 (en) * 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
DK2741740T3 (en) 2011-08-12 2017-06-06 Merial Inc VACUUM-SUPPORTED CONSERVATION OF BIOLOGICAL PRODUCTS, IN PARTICULAR OF VACCINES
EP2791326A4 (en) * 2011-12-16 2015-09-02 Univ New York State Res Found NEW WEARED POLIOVIRUS: PV-1-MONO-CRE-X
CN104302316A (zh) * 2012-05-17 2015-01-21 佐蒂斯有限责任公司 在断奶之前对抗猪繁殖与呼吸综合征(prrs)病毒的有效疫苗接种
PL2874656T3 (pl) 2012-07-17 2018-04-30 Merial, Inc. Atenuowane szczepionki przeciw grypie świń oraz ich sposoby wytwarzania i zastosowanie
WO2015183895A1 (en) * 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US20180010136A1 (en) * 2014-05-30 2018-01-11 John Francis Hunt, III Methods for Altering Polypeptide Expression
TWI745278B (zh) 2014-10-10 2021-11-11 以色列商艾畢克生物實驗有限公司 發泡性降低之疫苗組合物
EP3050962A1 (en) * 2015-01-28 2016-08-03 Institut Pasteur RNA virus attenuation by alteration of mutational robustness and sequence space
EP3303571A4 (en) * 2015-06-04 2018-10-17 The University of Hong Kong Live-attenuated virus and methods of production and use

Also Published As

Publication number Publication date
EA201991319A1 (ru) 2019-11-29
AU2017367644A1 (en) 2019-06-13
CN110225765A (zh) 2019-09-10
WO2018102586A1 (en) 2018-06-07
CN110225765B (zh) 2024-03-12
US10548967B2 (en) 2020-02-04
EP3548078A1 (en) 2019-10-09
JP2020502080A (ja) 2020-01-23
US20180147276A1 (en) 2018-05-31
PH12019501173A1 (en) 2019-10-28
KR20190099218A (ko) 2019-08-26
CA3045315A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
BR112017009374A2 (pt) ?composições de ramnolipídeo de baixa viscosidade concentradas?
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
UY36499A (es) Uso de picolinamidas como fungicidas
CY1121602T1 (el) Συνθεση της κοπανλισιμπης και του διυδροχλωρικου αλατος της
MX2015016755A (es) Reagrupamiento del virus de influenza.
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
CR20170005A (es) Derivados de insoindolina
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
DK3630136T3 (da) Sammensætninger, der omfatter bakteriestammer
DK3638271T3 (da) Sammensætninger omfattende bakteriestammer
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
BR112018010692A8 (pt) composições imunoestimuladoras, usos de melanina ou de um precursor da melanina e método para obter uma composição imunoestimuladora
BR112018006870A2 (pt) nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
BR112019010830A2 (pt) vacinas atenuadas de influenza suína e métodos de produção e uso das mesmas
BR112016016672A2 (pt) Uso de uma composição
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
CL2017001258A1 (es) Generación de inmunidad

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements